IceCure Medical Enrolls First Patients in FDA-Approved ChoICE Study

IceCure Medical Ltd. has enrolled its first two patients in the ChoICE post-market clinical study, which assesses the FDA-cleared ProSense cryoablation system for breast cancer treatment. The study aims to enroll about 400 patients across 30 clinical sites in the U.S. to generate real-world evidence for broader clinical adoption and reimbursement. This milestone is significant for the company's U.S. commercialization strategy following the FDA's authorization of the ProSense system.